MAURA MURPHY,KIRK DINEHART,PATRICIA HURTER,PATRICK CONNELLY,YONG CUI
申请号：
IN7312/DELNP/2006
公开号：
IN264690B
申请日:
2006.12.05
申请国别(地区):
IN
年份:
2015
代理人:
摘要：
The inventors have discovered forms and formulations of VX-950 having improved bioavailability relative to crystalline VX-950. These forms and formulations are useful for treating HCV infection. Accordingly, in one aspect, the invention features a preparation of amorphous VX-950, for example a preparation of VX-950 that is substantially pure of impurities and/or crystalline VX-950. For example, in one embodiment, the invention features formulations containing VX-950 in the amorphous form, which enhances the metastable solubility of VX-950 relative to the crystalline form, and thus provides improved bioavailability.
